Read More Pharma Industry News Ateganosine Phase 3 marks inflection point for MAIA Biotechnology with 2026 milestones in focus Find out how MAIA Biotechnology’s Phase 3 ateganosine trial and 2026 milestones could reshape its regulatory path and investor narrative. bySoujanya RaviJanuary 23, 2026